Roberto Labianca
Impact in
- Oncology top 0.05%
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Screening and Detection
- Cancer Treatment and Pharmacology
- Internal Medicine top 0.5%
Papers in
- Oncology 193
- Colorectal Cancer Treatments and Studies 125
- Colorectal Cancer Surgical Treatments 39
- Cancer Treatment and Pharmacology 34
- Pancreatic and Hepatic Oncology Research 29
-
- Gastric Cancer Management and Outcomes 70
- Lung Cancer Treatments and Mutations 20
- Co-authors
- Giordano Beretta (45 shared papers)Daniel J. Sargent (25 shared papers)Bernard Nordlinger (8 shared papers)Eric Van Cutsem (23 shared papers)Mario Mandalà (22 shared papers)Stefania Mosconi (23 shared papers)Alberto Zaniboni (43 shared papers)Richard M. Goldberg (10 shared papers)
- Journals
- Journal of Clinical Oncology (78 papers)Annals of Oncology (49 papers)European Journal of Cancer (18 papers)British Journal of Cancer (17 papers)Critical Reviews in Oncology/Hematology (11 papers)
- Partner nations
- ItalyFranceUnited States
In The Last Decade
Roberto Labianca
320 papers receiving 22.0k citations
Roberto Labianca's Hit Papers
Peers
Comparison fields: 5 of 151
- Oncology 12.2k
- Internal Medicine 800
- Pathology and Forensic Medicine 3.7k
- Cancer Research 2.4k
- Hepatology 1.1k
Countries citing papers authored by Roberto Labianca
This map shows the geographic impact of Roberto Labianca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Labianca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Labianca more than expected).
Fields of papers citing papers by Roberto Labianca
This network shows the impact of papers produced by Roberto Labianca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Labianca. The network helps show where Roberto Labianca may publish in the future.
Co-authors
The 25 scholars most cited alongside Roberto Labianca, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 328 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer Hit paper breakdown → | 2010 | 1173 |
| 2 | Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2013 | 1105 |
| 3 | Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial Hit paper breakdown → | 2009 | 931 |
| 4 | Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Hit paper breakdown → | 1998 | 822 |
| 5 | Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial Hit paper breakdown → | 2005 | 783 |
| 6 | Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2020 | 779 |
| 7 | Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much? Hit paper breakdown → | 2004 | 776 |
| 8 | A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients Hit paper breakdown → | 2001 | 751 |
| 9 | Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials Hit paper breakdown → | 2005 | 542 |
| 10 | 2009 | 499 | |
| 11 | Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study Hit paper breakdown → | 2009 | 460 |
| 12 | Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials Hit paper breakdown → | 2008 | 428 |
| 13 | DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy Hit paper breakdown → | 2011 | 419 |
| 14 | Addressing the challenges of pancreatic cancer: Future directions for improving outcomes Hit paper breakdown → | 2014 | 400 |
| 15 | 2007 | 398 | |
| 16 | 2003 | 384 | |
| 17 | Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial Hit paper breakdown → | 2013 | 381 |
| 18 | 1999 | 350 | |
| 19 | 2008 | 348 | |
| 20 | 1999 | 334 |
About Roberto Labianca
Roberto Labianca is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Surgery and Cancer Research, having authored 328 papers that have together received 22.7k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (125 papers), Gastric Cancer Management and Outcomes (70 papers), Genetic factors in colorectal cancer (45 papers), Colorectal Cancer Surgical Treatments (39 papers), Cancer Treatment and Pharmacology (34 papers), Pancreatic and Hepatic Oncology Research (29 papers), Lung Cancer Treatments and Mutations (20 papers) and Colorectal and Anal Carcinomas (17 papers). The work is most often cited by research in Oncology (12.2k citations), Internal Medicine (800 citations), Pathology and Forensic Medicine (3.7k citations), Cancer Research (2.4k citations) and Hepatology (1.1k citations). Roberto Labianca has collaborated with scholars based in Italy, France and United States. Frequent co-authors include Giordano Beretta, Daniel J. Sargent, Bernard Nordlinger, Eric Van Cutsem, Mario Mandalà, Stefania Mosconi, Alberto Zaniboni, Richard M. Goldberg, Stefano Cascinu and Sandro Barni. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, British Journal of Cancer and Critical Reviews in Oncology/Hematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.